BioSpace News Archive

Acquisition of external cardiac monitoring technologies and services provider to expand rhythm management diagnostics portfolio and capabilities

Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will host a virtual investor event titled Pegcetacoplan: Advancing the First Potential Treatment for Geographic Atrophy (GA) from 10:00 a.m. to noon ET on January 28, 2021.

Science 37’s flexible Science 37 Certified program provides contract research organizations (CROs) with direct access to its Operating System to enable decentralized trial solutions.

Piramal Pharma Limited’s Pharma Solutions business, a leading contract development and manufacturing organization (CDMO), today announced that it is providing Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) with GMP manufacturing of sterile fill/finish drug product to support their developmental product as it enters into a first-in-humans clinical study.

Rapid advances in technology and high disease burden worldwide are anticipated to proliferate animal vaccines market share at a considerable pace over 2019-2025.

Rising prevalence of parasites and diseases among farmed fish is expected to propel aquaculture healthcare market share over the forecast period.

The Institute for Life Science Entrepreneurship (ILSE) at Kean University has created Biotech LaunchPad, a comprehensive suite of business and scientific services to support the commercial success of life science startups.

Pathogenic bacteria in humans are developing resistance to antibiotics much faster than expected. Now, computational research at Chalmers University of Technology, Sweden, shows that one reason could be significant genetic transfer between bacteria in our ecosystems and to humans.

Aquaculture vaccines offer superior protection against contagions and do not project any adverse effects related to antibodies like resistance and disease recurrence.

Emergence of sophisticated healthcare infrastructure and the consistent deployment of advanced technological solutions will accelerate the demand for atrial fibrillation devices through the coming years.